BioSpace News Archive

The infectious diseases market is expected to reach $150 billion in sales by 2029, with three pharma giants reaping most of its benefits, according to data analytics and consultancy GlobalData.

Despite the lifting of the FDA’s partial clinical hold, Gilead will discontinue magrolimab’s development in higher-risk myelodysplastic syndromes after a Phase III study met the bar for futility.

With an upfront payment of $310 million in cash, Roche is partnering with Alnylam to develop the latter’s RNA interference candidate zilebesiran for hypertension patients with high cardiovascular risk.

The Danish vaccine maker’s respiratory syncytial virus candidate did not meet all primary endpoints in a late-stage study in older adults and the company is discontinuing the program.

James Ellis, an authority on employer branding for small businesses and biotechs, weighs in on the best ways to earn candidates’ trust.

Company shares fell over 50% after two late-stage studies failed to demonstrate vision improvements in patients with diabetes macular edema.

Alphatec Holdings, Inc. announced today that management will participate in the following investor events.

Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) (the “Company” or “Inspira Technologies”), a company aiming to revolutionize acute respiratory care, is proud to announce it has received International Organization for Standardization (ISO) 13485:2016 Standard Certification, which is the international standard for quality management systems within the medical device industry, and a requirement for EU regulatory approval.

Senda Biosciences, Inc. today announced the appointment of Igor Matushansky, M.D., Ph.D., as Chief Medical Officer.

Fapon, a leading life science company, will showcase its latest innovations in in-vitro diagnostic and biopharma solutions at the 2023 American Association of Clinical Chemistry Scientific Meeting and Clinical Lab Expo from July 25 to 27.